Analisis Vasektomi Sebagai Faktor Risiko Kejadian Kanker Prostat
Abstract
Abstract. Vasectomy or vas ligation is a method of contraception in men by cutting and tying the right and left of vas deferens with the aim of preventing spermatozoa from coming out during ejaculation. Vasectomy cannot be separated from long-term health risks, one of which is that men who undergo vasectomies have a 15% higher risk of developing prostate cancer overall. Prostate cancer is a type of cancer that develops from gland cells that produce prostate fluid combined with semen. The aim of this study is to provide information to readers regarding the relationship between vasectomy as a risk factor for prostate cancer. This research uses a scoping review study to identify and report several articles through Pubmed, ScienceDirect, SpringerLink, Taylor and Francis. The PRISMA diagram method was used in this research and resulted in nineteen articles that met the inclusion and eligibilty criteria. Based on results of the analysis, there are ten articles that can conclude that vasectomy could increase the risk of prostate cancer and nine articles concluded that vasectomy could not increase the risk of prostate cancer.
Abstrak. Vasektomi atau vas ligation merupakan salah satu metode kontrasepsi pada pria dengan prosedur pemotongan dan pengikatan pada vas deferens kanan dan kiri dengan tujuan untuk mencegah spermatozoa keluar saat ejakulasi. Vasektomi tidak lepas dari dampak risiko kesehatan yang panjang, salah satunya yaitu pria yang menjalani vasektomi memiliki risiko 15% lebih tinggi terkena kanker prostat secara keseluruhan. Kanker prostat merupakan jenis kanker yang berkembang dari sel kelenjar yang menghasilkan cairan prostat yang tergabung dengan semen. Tujuan dari penelitian ini yaitu untuk memberikan informasi kepada pembaca mengenai hubungan vasektomi sebagai faktor risiko kejadian kanker prostat. Penelitian ini menggunakan studi scoping review untuk mengidentifikasi dan melaporkan beberapa artikel melalui sumber PubMed, ScienceDirect, SpringerLink, dan Taylor and Francis. Metode diagram PRISMA digunakan dalam penelitian ini dan menghasilkan sembilan belas artikel yang memenuhi kriteria inklusi dan kelayakan. Berdasarkan hasil analisis dan pembahasan dari uraian artikel penelitian yang ditinjau, sepuluh artikel menyimpulkan bahwa vasektomi dapat meningkatkan risiko kejadian kanker prostat dan sembilan artikel menyimpulkan bahwa vasektomi tidak dapat meningkatkan risiko kejadian kanker prostat.
References
M. T. Davenport, C. A. Zhang, J. T. Leppert, J. D. Brooks, dan M. L. Eisenberg, “Vasectomy and the risk of prostate cancer in a prospective US Cohort: Data from the NIH-AARP Diet and Health Study,” Andrology, vol. 7, no. 2, hal. 178–183, 2019, doi: 10.1111/andr.12570.
P. J. Schwingl, O. Meirik, N. Kapp, dan T. M. M. Farley, “Prostate cancer and vasectomy: a hospital-based case-control study in China, Nepal and the Republic of Korea,” Contraception, vol. 79, no. 5, hal. 363–368, 2009, doi: 10.1016/j.contraception.2008.11.015.
E. M. John et al., “Vasectomy and prostate cancer: results from a multiethnic case-control study,” JNCI J. Natl. Cancer Inst., vol. 87, no. 9, hal. 662–669, 1995, doi: NCI: Journal of the National Cancer Institute.
B. Cox, M. J. Sneyd, C. Paul, B. Delahunt, dan D. C. G. Skegg, “Vasectomy and risk of prostate cancer,” JAMA, vol. 287, no. 23, hal. 3110–3115, 2002, doi: 10.1001/jama.287.23.3110.
M. Nayan et al., “Vasectomy and risk of prostate cancer: population based matched cohort study,” BMJ, vol. 355, hal. i5546, 2016, doi: 10.1136/bmj.i5546.
K. Smith et al., “Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC),” J. Clin. Oncol., vol. 35, no. 12, hal. 1297–1303, 2017, doi: 10.1200/JCO.2016.70.0062.
S. M. Lesko, C. Louik, R. Vezina, L. Rosenberg, dan S. Shapiro, “Vasectomy and prostate cancer,” J. Urol., vol. 161, no. 6, hal. 1848–1853, 1999.
E. J. Jacobs, R. L. Anderson, V. L. Stevens, C. C. Newton, T. Gansler, dan S. M. Gapstur, “Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort,” J. Clin. Oncol., vol. 34, no. 32, hal. 3880–3885, 2016, doi: 10.1200/JCO.2015.66.2361.
H. N et al., “SEER Cancer Statistics Review (CSR) 1975-2014,” 2021.
K. Zhu et al., “Vasectomy and prostate cancer: a case-control study in a health maintenance organization,” Am. J. Epidemiol., vol. 144, no. 8, hal. 717–722, 1996, doi: 10.1093/oxfordjournals.aje.a008994.
E. A. Platz, B. B. Yeole, E. Cho, D. J. Jussawalla, E. Giovannucci, dan A. Ascherio, “Vasectomy and prostate cancer: a case-control study in India,” Int. J. Epidemiol., vol. 26, no. 5, hal. 933–938, 1997, doi: 10.1093/ije/26.5.933.
H. Seikkula et al., “Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort,” Cancer Epidemiol., vol. 64, hal. 101631, 2020, doi: 10.1016/j.canep.2019.101631.
M. M. Siddiqui et al., “Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study,” J. Clin. Oncol., vol. 20, no. 32, hal. 3033–3038, 2014, doi: 10.1200/JCO.2013.54.8446.
[J. F. Emard, G. Drouin, J. P. Thouez, dan P. Ghadirian, “Vasectomy and prostate cancer in Québec, Canada,” Health Place, vol. 7, no. 2, hal. 131–139, 2001, doi: 10.1016/s1353-8292(01)00005-3.
S. Rohrmann, D. N. Paltoo, E. A. Platz, S. C. Hoffman, G. W. Comstock, dan K. J. Helzlsouer, “Association of vasectomy and prostate cancer among men in a Maryland cohort,” Cancer Causes Control, vol. 16, no. 10, hal. 1189–1194, 2005, doi: 10.1007/s10552-005-0304-8.
[E. Giovannucci, A. Ascherio, E. B. Rimm, G. A. Colditz, M. J. Stampfer, dan W. C. Willett, “A prospective cohort study of vasectomy and prostate cancer in US men,” JAMA, vol. 169, no. 7, hal. 873–877, 1993.
R. B. Hayes et al., “Vasectomy and prostate cancer in US blacks and whites,” Am. J. Epidemiol., vol. 137, no. 3, hal. 263–269, 1993, doi: 10.1093/oxfordjournals.aje.a116673.
S. K. Holt, C. A. Salinas, dan J. L. Stanford, “Vasectomy and the risk of prostate cancer,” J. Urol., vol. 180, no. 6, hal. 2565–2568, 2008, doi: 10.1016/j.juro.2008.08.042.
J. Shoag et al., “Vasectomy and Risk of Prostate Cancer in a Screening Trial,” Cancer Epidemiol. Biomarkers Prev., vol. 26, no. 11, hal. 1653–1659, 2017, doi: 10.1158/1055-9965.EPI-16-0776.
Adila Putri Ramandhita and L. Hanum, “Efek Antikanker Nanopartikel Alginat Ekstrak Etanol Daun Sirsak (Annona muricata Linn) pada Kultur Sel Kanker Hepar (HepG2),” Jurnal Riset Kedokteran, vol. 1, no. 2, pp. 130–133, Feb. 2022, doi: 10.29313/jrk.v1i2.566.
A. Husby, J. Wohlfahrt, dan M. Melbye, “Vasectomy and Prostate Cancer Risk: A 38-Year Nationwide Cohort Study,” J. Natl. Cancer Inst., vol. 112, no. 1, hal. 71–77, 2020, doi: 10.1093/jnci/djz099.
F. Yang et al., “Review of Vasectomy Complications and Safety Concerns. World J Mens Health,” World J Mens Heal., vol. 39, no. 3, hal. 406–418, 2021, doi: 10.5534/wjmh.200073.
BKKBN, “Rencana Strategis Badan Kependudukan dan Keluarga Berencana Nasional Tahun 2015-2019 (REVISI),” vol. 1, 2016.
M. A. Wulansari, E. Sulistyaningsih, dan T. Susanto, “The differenced of characteristics of contraceptive method of condom and vasectomy: A cross-sectional study among married of male in Indonesia,” Nurs Commun, vol. 4, no. 4, hal. 111, 2020.
J. E. Long, M. S. Lee, dan D. L. Blithe, “Male contraceptive development: Update on novel hormonal and nonhormonal methods,” Clin Chem, vol. 65, no. 1, hal. 153–160, 2019.
“CDC. What Is Prostate Cancer?,” American Cancer Society, 2020. https://www.pcf.org/about-prostate-cancer/what-is-prostate-cancer/ (diakses 4 Januari 2024).
“Who Is at Risk?,” 2023. https://www.cdc.gov/cancer/prostate/basic_info/risk_factors.htm#:~:text=The most common risk factor,family history of prostate cancer
K. A. Nelson dan J. S. Witte, “Androgen Receptor CAG Repeats and Prostate Cancer,” Am. J. Epidemiol., vol. 155, no. 10, hal. 883–890, 2002, doi: 10.1093/aje/155.10.883.
